0000000000217172

AUTHOR

J.e. Räsänen

showing 3 related works from this author

Hyperspectral imaging reveals spectral differences and can distinguish malignant melanoma from pigmented basal cell carcinomas : A pilot study

2021

Pigmented basal cell carcinomas can be difficult to distinguish from melanocytic tumours. Hyperspectral imaging is a non-invasive imaging technique that measures the reflectance spectra of skin in vivo. The aim of this prospective pilot study was to use a convolutional neural network classifier in hyperspectral images for differential diagnosis between pigmented basal cell carcinomas and melanoma. A total of 26 pigmented lesions (10 pigmented basal cell carcinomas, 12 melanomas in situ, 4 invasive melanomas) were imaged with hyperspectral imaging and excised for histopathological diagnosis. For 2-class classifier (melanocytic tumours vs pigmented basal cell carcinomas) using the majority of…

Pathologymedicine.medical_specialtySkin Neoplasms010504 meteorology & atmospheric sciencesneural network3122 Cancers0211 other engineering and technologiesmalignant melanomaPilot Projects02 engineering and technologyneuroverkotDermatologytyvisolusyöpä3121 Internal medicine01 natural sciencesSensitivity and SpecificityLesionihosyöpäDiagnosis Differentialbasal cell carcinomamedicineHumansBasal cell carcinomaBasal cellProspective StudiesMelanoma021101 geological & geomatics engineering0105 earth and related environmental sciencesbusiness.industryMelanomaspektrikuvausHyperspectral imagingdeep learningGeneral MedicineHyperspectral Imagingdiagnostiikkamedicine.disease3126 Surgery anesthesiology intensive care radiologyReflectivityConfidence interval3. Good healthkoneoppiminenCarcinoma Basal CellRL1-8033121 General medicine internal medicine and other clinical medicinemedicine.symptomDifferential diagnosisbusiness
researchProduct

Ablative fractional laser-assisted photodynamic therapy for lentigo maligna: a prospective pilot study.

2019

Background Lentigo maligna (LM) is an in‐situ form of melanoma carrying a risk of progression to invasive lentigo maligna melanoma (LMM). LM poses a clinical challenge, with subclinical extension and high recurrence rates after incomplete surgery. Alternative treatment methods have been investigated with varying results. Photodynamic therapy (PDT) with methylaminolaevulinate (MAL) has already proved promising in this respect. Objectives To investigate the efficacy of ablative fractional laser (AFL)‐assisted PDT with 5‐aminolaevulinic acid nanoemulsion (BF‐200 ALA) for treating LM. Methods In this non‐sponsored, prospective pilot study ten histologically verified LMs were treated with AFL‐as…

Malemedicine.medical_specialtyBF-200 ALASkin NeoplasmsBiolääketieteet - Biomedicinemedicine.medical_treatmentFractional laserPhotodynamic therapyPilot ProjectsDermatologyLentigo malignalaserhoitoHutchinson's Melanotic Freckle030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineablative fractional laser5-aminolaevulinic acid nanoemulsionAblative casemedicineHumansmelanoomaProspective StudiesLentigo maligna melanomaSubclinical infectionAgedAged 80 and overbusiness.industryRopivacaineMelanomaSisätaudit - Internal medicineAminolevulinic AcidMiddle Agedmedicine.diseaseCombined Modality Therapy3. Good healthInfectious Diseasesphotodynamic therapyfotodynaaminen hoitoPhotochemotherapy030220 oncology & carcinogenesisFemaleRadiologyLaser Therapylentigo malignabusinessmedicine.drugJournal of the European Academy of Dermatology and Venereology : JEADVReferences
researchProduct

Hexyl aminolevulinate, 5‐aminolevulinic acid nanoemulsion and methyl aminolevulinate in photodynamic therapy of non‐aggressive basal cell carcinomas:…

2020

Background In the photodynamic therapy (PDT) of non‐aggressive basal cell carcinomas (BCCs), 5‐aminolevulinic acid nanoemulsion (BF‐200ALA) has shown non‐inferior efficacy when compared with methyl aminolevulinate (MAL), a widely used photosensitizer. Hexyl aminolevulinate (HAL) is an interesting alternative photosensitizer. To our knowledge, this is the first study using HAL‐PDT in the treatment of BCCs. Objectives To compare the histological clearance, tolerability (pain and post‐treatment reaction), and cosmetic outcome of MAL, BF‐200 ALA, and low‐concentration HAL in the PDT of non‐aggressive BCCs. Methods Ninety‐eight histologically verified non‐aggressive BCCs met the inclusion criter…

Skin Neoplasmsmedicine.medical_treatmentPhotodynamic therapyGastroenterologylaw.invention030207 dermatology & venereal diseases0302 clinical medicineMethyl aminolevulinateRandomized controlled trialnon-aggressive basal cell carcinomalawTOPICAL IMIQUIMODProspective Studies10. No inequalityProspective cohort studyPhotosensitizing AgentsSisätaudit - Internal medicinePAINkarsinoomat3. Good healthTreatment OutcomeInfectious Diseasesphotodynamic therapyTolerabilityFluorouracil030220 oncology & carcinogenesisBOWENS-DISEASEmedicine.symptommedicine.drugmedicine.medical_specialtyBiolääketieteet - Biomedicine3122 Cancersmethyl aminolevulinateEUROPEAN GUIDELINESDermatologySINGLE-BLINDLesion03 medical and health scienceshexyl aminolevulinatenon‐aggressive basal cell carcinomaSyöpätaudit - CancersInternal medicineparasitic diseasesMANAGEMENTmedicineCarcinomaHumansANESTHESIAbusiness.industryAminolevulinic Acidmedicine.disease5‐aminolevulinic acid nanoemulsionFLUOROURACILPROTOPORPHYRIN IX FORMATIONfotodynaaminen hoitoPhotochemotherapyCarcinoma Basal Cell5-aminolevulinic acid nanoemulsionbusinessSKINJournal of the European Academy of Dermatology and Venereology
researchProduct